Latest Licensing Deals News

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Weebit Nano has reported a remarkable 300% revenue increase to $4.4 million in FY25, driven by expanding licensing deals for its advanced ReRAM technology.

Weebit Nano Limited reported a strong FY25 with revenues surging over fourfold to $4.4 million and a narrowed net loss of $38.4 million, driven by key licensing deals and progress towards automotive-grade ReRAM qualification.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

Nine Entertainment Co. Holdings Limited reported a modest dip in FY25 net profit to $133.3 million amid rising costs, while announcing a substantial special dividend tied to the imminent sale of its Domain stake.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Metallium Ltd has partnered with Rice University to advance its Flash Joule Heating technology, targeting a breakthrough in rare earth element separation that could reduce Western dependence on Chinese refining. This collaboration seeks to simplify or bypass the costly solvent extraction process dominating the industry.